N※N

FDA Leaders Clash with Vaccine Chief Over Omicron Protection Claims

  //food-wine.news-articles.net/content/2026/02/12 .. accine-chief-over-omicron-protection-claims.html
  Published in Food and Wine on Thursday, February 12th 2026 at 5:42 GMT by Seattle Times
      Locales: Washington, UNITED STATES

Former FDA Leaders Escalate Dispute with Vaccine Chief Over Omicron Protection Claims

By Joseph Morton

Washington D.C. - February 12, 2026 - A growing rift within the Food and Drug Administration has burst into public view, as twelve former FDA commissioners and senior leaders have issued a scathing rebuke of Dr. Joshua Sharpless, the agency's current Director of the Center for Biologics Evaluation and Research (CBER) - often referred to as the vaccine chief. The former officials allege Dr. Sharpless has been misleading the public regarding the efficacy of existing COVID-19 vaccines against the ever-evolving Omicron variant, and its numerous subvariants.

The dispute, detailed in a publicly released joint letter today, centers around concerns that Dr. Sharpless's repeated assertions of "substantial protection" offered by the vaccines, even against Omicron, are not adequately supported by the latest scientific data. The former leaders argue that such statements risk fostering a dangerous complacency, particularly amongst those who have not yet received recommended booster doses.

"The core issue is transparency," stated Dr. Richard Wyckoff, a former FDA deputy commissioner and a prominent signatory to the letter. "While it's true the original vaccines and initial boosters offered significant protection against severe outcomes, that protection has demonstrably waned, especially against Omicron and its successive strains. To downplay this fact, even with the intention of promoting vaccination, ultimately erodes public trust and potentially hinders future public health initiatives."

The controversy highlights a fundamental disagreement within the FDA about the optimal strategy for communicating complex scientific information to the public during a pandemic characterized by rapid viral evolution. Dr. Sharpless, in a series of interviews over the past year, has consistently emphasized the vaccines' continued ability to prevent severe illness, hospitalization, and death, even as their effectiveness against symptomatic infection diminishes. He maintains that focusing on these key outcomes is the most effective way to encourage continued vaccination and boost uptake of updated boosters.

However, the former FDA leaders contend that this approach is disingenuous and fails to provide the public with a complete and accurate picture of the current situation. They point to data, published in peer-reviewed journals such as The Lancet and The New England Journal of Medicine, which indicate a significant reduction in vaccine effectiveness against symptomatic infection with Omicron and its subvariants - BA.4, BA.5, and the now-dominant XBB.1.5 lineage. These studies also reveal the limited duration of protection offered by boosters, necessitating frequent updates to maintain a robust immune response.

"We're not saying the vaccines are worthless," clarified Dr. Margaret Hamburg, a former FDA commissioner who also signed the letter. "They still offer some protection, and vaccination remains a crucial public health measure. However, we need to be honest with the American people about what these vaccines can and cannot do. Presenting an overly optimistic view, without acknowledging the limitations, is simply not responsible."

The escalating conflict comes at a critical juncture. The winter months have seen a resurgence of COVID-19 cases, driven largely by the highly transmissible XBB.1.5 variant. Hospitalization rates, while significantly lower than during earlier waves of the pandemic, have begun to creep upwards, raising concerns among public health officials. The debate over vaccine messaging is further complicated by the ongoing development of new, variant-specific vaccines, and the logistical challenges of ensuring equitable access to these updated boosters.

Several analysts suggest the disagreement reflects a broader tension within the FDA regarding the balance between promoting public health and maintaining scientific integrity. The agency has faced intense political pressure throughout the pandemic, and some observers believe Dr. Sharpless may be attempting to navigate these pressures by emphasizing the positive aspects of vaccination, even if it means downplaying certain limitations. Dr. Sharpless has yet to issue a public response to the criticism leveled by the former FDA leaders, although sources within the agency indicate internal discussions are ongoing. The situation is being closely monitored by Congress, with several lawmakers signaling their intention to hold hearings to examine the agency's communication strategy regarding COVID-19 vaccines and the evolving threat posed by new variants.